Pivotal Life Sciences | Portfolio Company News

MapLight Therapeutics Closes $225 Million Series C Funding Round to Advance Pipeline of Central Nervous System Therapeutics

October 30, 2023

Arcutis Announces Pricing of $100 Million Public Offering

October 19, 2023

Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies

September 27, 2023

Study Confirming Overwhelming Reduction in Bleeding of the Dual- Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late- Breaker Oral Presentation at the American Heart Association Scientific Sessions

September 26, 2023

Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

September 26, 2023

Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany

September 20, 2023

Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)

September 18, 2023

MapLight Therapeutics Announces Successful Completion of Second Phase 1 Clinical Trial of the Novel Muscarinic Receptor Agonist ML-007

August 24, 2023

OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints for the Treatment of Inflammation and Pain Following Cataract Surgery

August 08, 2023

Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors

August 07, 2023

IO Biotech, Inc. Announces $75 Million Private Placement Financing

August 07, 2023

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

Occulis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares

Obsidian Therapeutics Announces Dr. Madan Jagasia as Chief Executive Officer and Other Leadership Appointments

Evommune raises $50M to fund clinical trials in skin diseases

Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline

December 06, 2022

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP

November 01, 2022

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated

October 24, 2022

1 2 3